Drug intelligence / Profile preview

ulapualide a

Development stage: Preclinical
Modality: Peptides, Small Molecules

Overview

Ulapualide A is a naturally occurring marine macrolide isolated from the egg masses of certain nudibranchs. It belongs to the class of trisoxazole-based macrolides and is structurally characterized as a diterpene lactone. Ulapualide A exhibits potent antitumor activity and acts as an actin-depolymerizing agent, disrupting cytoskeletal integrity in cells. Its mechanism involves binding to actin filaments and promoting their depolymerization, which leads to profound effects on cell adhesion and morphology. The compound has been studied for its unique stereochemistry and structure-activity relationships with synthetic analogues[1][2][4][6].

Other names: ulapualide atrisoxazole-based macrolidemarine macrolide toxin

Targets

Actin filament proteins

Beyond the preview

Go deeper on ulapualide a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ulapualide a.

Explore the full profile